Research Topic: CAR T-cell therapy

Schizophyllum commune infection following chimeric antigen receptor T-cell therapy in a patient with lymphoma

mycolabadmin

A 71-year-old woman receiving CAR T-cell therapy for lymphoma developed a rare fungal lung infection caused by Schizophyllum commune six months after treatment. The infection presented similarly to other fungal diseases affecting the lungs and was diagnosed through bronchoscopy and fungal culture despite negative blood antibody tests. Standard antifungal medication (voriconazole) taken by mouth for four months completely resolved the infection, highlighting the need to consider rare fungi in patients receiving advanced cancer immunotherapies.

Read More »

Invasive Fungal Disease is Rare in Multiple Myeloma Patients Treated with BCMA CAR-T Therapy

mycolabadmin

Researchers studied patients with multiple myeloma who received a new type of cancer treatment called BCMA CAR-T cell therapy. While this powerful therapy can sometimes increase infection risk, the study found that serious fungal infections occurred in only a small percentage of patients (1.7%). However, when these fungal infections did occur, they were often severe and potentially life-threatening, particularly in patients who experienced significant side effects from the therapy.

Read More »
Scroll to Top